We think opportunities abound in the sector.
The financing will support the commercialization of BioXcel's recently approved Igalmi sublingual film for agitation associated with schizophrenia or bipolar I or II disorder.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.
| Website: | www.bioxceltherapeutics.com |
| Email: | info@bioxceltherapeutics.com |
| Main Phone: | +1 475 238-6837 |
| Address: | 555 Long Wharf Drive |
| Address 2: | 12th Floor |
| State: | CT |
| City / Town: | New Haven |
| Country: | US |
| Postal Code: | 06511 |
| Exchange: | NSC |
| CEO: | Vimal Mehta |
| Employees: | 50 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
We think opportunities abound in the sector.
The financing will support the commercialization of BioXcel's recently approved Igalmi sublingual film for agitation associated with schizophrenia or bipolar I or II disorder.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
